This retrospective multi-institutional case series evaluated nemolizumab (an IL-31 receptor alpha antagonist) for treatment-refractory cutaneous adverse events (CAEs) in patients with cancer, assessing its safety and efficacy in a population where standard therapies had failed.
Retrospective design with no control group limits causal inference; small case series sample size reduces generalizability; heterogeneity in underlying cancers and prior treatments may confound outcomes.
Nemolizumab may be a consideration for oncology patients with refractory cutaneous adverse events who have not responded to standard treatments. Clinicians should weigh potential benefit against the limited evidence base from this small retrospective series.
Explore related topics
